Stroke RSS Page 10

Filtered By:
Source: Thrombosis Research
Condition: Thrombosis

This page shows you your search results in order of relevance. This is page number 10.

Order by Relevance | Date

Total 219 results found since Jan 2013.

Effects of rivaroxaban on coagulation tests in patients with non-valvular atrial fibrillation under real-life conditions
Novel oral anticoagulants (NOACs), such as direct factor Xa inhibitors, are effective alternatives for anticoagulation therapy in stroke prevention in atrial fibrillation patients.
Source: Thrombosis Research - March 7, 2017 Category: Hematology Authors: V.M. Silva, M. Scanavacca, F. Darrieux, C. Cavalheiro-Filho, C.C. Strunz Tags: Letter to the Editors-in-Chief Source Type: research

Depression and post-traumatic stress disorder in individuals with hereditary hemorrhagic telangiectasia: A cross-sectional survey
Hereditary hemorrhagic telangiectasia (HHT) is characterized by frequent severe bleeding, particularly epistaxis, and life-threatening complications including stroke, brain abscess and heart failure. The psychological impact of HHT is not known. We conducted this cross sectional study to determine the prevalence of depression and post-traumatic stress disorder (PTSD) related to HHT.
Source: Thrombosis Research - March 7, 2017 Category: Hematology Authors: Shruti Chaturvedi, Marianne Clancy, Nicole Schaefer, Olalekan Oluwole, Keith McCrae Tags: Full Length Article Source Type: research

Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trial
The ROCKET AF study evaluated once-daily rivaroxaban versus dose-adjusted warfarin for the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF). In this analysis, we compared rivaroxaban with warfarin in patients with AF from China, East Asia, and the rest of the world (ROW).
Source: Thrombosis Research - April 13, 2017 Category: Hematology Authors: Yihong Sun, Dayi Hu, Susanna Stevens, Yuliya Lokhnygina, Richard C. Becker, Scott D. Berkowitz, G ünter Breithardt, Werner Hacke, Jonathan L. Halperin, Graeme J. Hankey, Kenneth W. Mahaffey, Christopher C. Nessel, Jonathan P. Piccini, Daniel E. Singer, K Tags: Full Length Article Source Type: research

Increased expression of TFPI in human carotid stenosis
Tissue factor (TF) pathway inhibitor (TFPI) is the physiological inhibitor of TF induced blood coagulation and two isoforms exists, TFPI α and TFPIβ. In atherosclerotic plaques, TFPI may inhibit TF activity and thrombus formation, which is the main cause of ischemic stroke in carotid artery disease. We aimed to identify the isoforms of TFPI present in human carotid plaques and potential sources of TFPI.
Source: Thrombosis Research - April 27, 2017 Category: Hematology Authors: Benedicte Stavik, Sverre Holm, Sandra Espada, Nina Iversen, Bj ørnar Sporsheim, Vigdis Bjerkeli, Tuva Børresdatter Dahl, Per Morten Sandset, Mona Skjelland, Terje Espevik, Grethe Skretting, Bente Halvorsen Tags: Full Length Article Source Type: research

β-Thromboglobulin and incident cardiovascular disease risk: The Atherosclerosis Risk in Communities study
Although it has been suggested that increased concentrations of activated platelet biomarkers are associated with increased risk of incident cardiovascular disease (CVD) in the general population, evidence for this association is still controversial. Thus, we tested the hypothesis that activated platelets, measured by higher concentrations of β-thromboglobulin, are associated with increased risk of incident CVD (coronary heart disease, heart failure ischemic stroke, and atrial fibrillation).
Source: Thrombosis Research - May 17, 2017 Category: Hematology Authors: Yasuhiko Kubota, Alvaro Alonso, Aaron R. Folsom Tags: Full Length Article Source Type: research

Stroke diagnosis associated with thrombophilia testing overutilization
Thrombophilia broadly defines inherited or acquired coagulation disorders associated with increased tendency to form intravascular thrombi [1,2]. Although thrombophilia testing may help providers understand the underlying pathophysiology of a thrombotic event, universal thrombophilia screening for unselected patients presenting with thromboembolism is not recommended [3 –5]. Results of studies in both inpatient and outpatient settings have shown that the clinical utility of thrombophilia tests in anticoagulation management is limited, which potentially decreases cost-effectiveness of the testing [6,7].
Source: Thrombosis Research - July 18, 2017 Category: Hematology Authors: Kibum Kim, Nicholas Cox, Daniel M. Witt Tags: Letter to the Editors-in-Chief Source Type: research

Outcomes of an online pharmacist-managed anticoagulation clinic for individuals on warfarin therapy living in rural communities
Warfarin is one of the oral anticoagulants used for the prevention of stroke in patients with atrial fibrillation and mechanical heart valves or the treatment of venous thromboembolism [1]. However, warfarin therapy is challenging not only because this drug is known to have a narrow therapeutic range and carry a risk of bleeding but also because it can be influenced by certain patient variables and potential drug –drug, drug–food, and drug–herb interactions. In Chinese patients, warfarin therapy is especially challenging because Chinese patients are more sensitive than Caucasians to the anticoagulant effect of warfar...
Source: Thrombosis Research - July 20, 2017 Category: Hematology Authors: Jinhua Zhang, Maobai Liu, Qiang Chen, Jianmei Wu, Hua Cao Tags: Letter to the Editors-in-Chief Source Type: research

Outpatient therapy for acute symptomatic pulmonary embolism diagnosed in the emergency department: Time to improve the evidence base
Pulmonary embolism (PE) remains a worldwide major public health issue [1 –4]. After myocardial infarction and stroke, PE is the third most common cause of vascular death. In addition, PE is the leading preventable cause of death in hospitalized patients [2]. Treatment of PE costs over 19 billion dollars annually in the USA [3], and more than 50% of that expenditure rel ates to the cost of in-patient care [4]. The initial decision to admit the patient diagnosed with acute symptomatic PE in the emergency department (ED) to the hospital or to treat the patient at home therefore has significant patient care and public health implications.
Source: Thrombosis Research - November 25, 2017 Category: Hematology Authors: David Jim énez, Roger D. Yusen Tags: Editorial Source Type: research

The effect of dabigatran on thrombin generation and coagulation assays in rabbit and human plasma
Dabigatran etexilate is widely used for stroke prevention in the patients with atrial fibrillation. The anticoagulation activity of dabigatran is not necessary monitored in routine clinical practice. We aimed to study the effect of dabigatran on thrombin generation (TG) and coagulation assays in rabbit and human plasma.
Source: Thrombosis Research - March 14, 2018 Category: Hematology Authors: Chi Zhang, Peizhe Zhang, Hongxia Li, Lianhua Han, Lei Zhang, Lei Zhang, Xiangjun Yang Tags: Full Length Article Source Type: research

Antidotes for the direct oral anticoagulants: What news?
The direct oral anticoagulants (DOACs) are recommended as the first-choice anticoagulants for both stroke prevention in patients with non-valvular atrial fibrillation and the treatment and secondary prevention of venous thromboembolism. DOACs cause bleeding, albeit less than warfarin. Most bleeding complications can be controlled by general reversal strategies and supportive care. However, in case of life-threatening bleeding, or when urgent invasive procedures are needed, a more rapid and thorough reversal may be required.
Source: Thrombosis Research - April 1, 2018 Category: Hematology Authors: S. Galliazzo, M.P. Donadini, W. Ageno Tags: Full Length Article Source Type: research

Dabigatran reduces endothelial permeability through inhibition of thrombin-induced cytoskeleton reorganization
Dabigatran etexilate (DE), a new oral anti-coagulant, is a direct thrombin inhibitor. Clinical trials showed the favorable benefit-to-risk profile of DE compared to warfarin for the prevention of ischemic stroke in patients with atrial fibrillation. Remarkably, patients treated with dabigatran showed reduced rates of intracerebral hemorrhage compared to warfarin. As the breakdown of endothelial barrier integrity is associated with hemorrhagic events and as thrombin increases endothelial permeability, we hypothesized that dabigatran preserves the endothelial barrier by inhibiting thrombin-induced permeability.
Source: Thrombosis Research - April 25, 2018 Category: Hematology Authors: Hyun-Jung Choi, Na-Eun Kim, Jayoung Kim, Sunho An, Seung-Hee Yang, Jimin Ha, Sunghee Cho, Il Kwon, Young Dae Kim, Hyo Suk Nam, Ji Hoe Heo Tags: Full Length Article Source Type: research

Dabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation
New oral anticoagulants are non-inferior compared with warfarin regarding stroke prevention in atrial fibrillation, with similar or decreased risk of bleeding. However, it is unclear whether high TTR warfarin is as effective and safe as NOACs. Our objective was to investigate efficacy and safety of apixaban, dabigatran or rivaroxaban compared with warfarin in clinical practice.
Source: Thrombosis Research - May 17, 2018 Category: Hematology Authors: Sara Sj älander, Vilhelm Sjögren, Henrik Renlund, Bo Norrving, Anders Själander Tags: Full Length Article Source Type: research

Prothrombotic mechanisms in patients with congenital p.Cys89Tyr mutation in CD59
Nonfunctioning CD59 is a major risk factor for stroke and hypercoagulability. Uncontrolled hemolysis causes massive MP release and endothelial heme damage. MAC attack on unprotected endothelium and platelet activation and aggregation with leukocytes mediate additional mechanisms leading to vascular occlusion. It is suggested that CD59 loss represents a major arterial prothrombotic factor in PNH and additional diseases.
Source: Thrombosis Research - June 11, 2018 Category: Hematology Authors: Adi Tabib, Issam Hindi, Netanel Karbian, Orly Zelig, Batla Falach, Dror Mevorach Tags: Full Length Article Source Type: research

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15